{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:14:13Z","timestamp":1793229253229,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jpsychires.2026.03.014","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:21:55Z","timestamp":1773249715000},"page":"294-297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Metabolic parameters as a predictor of relapse in patients with schizophrenia undergoing tapering of antipsychotics"],"prefix":"10.1016","volume":"197","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6268-925X","authenticated-orcid":false,"given":"Sofie Norlin","family":"M\u00f8lgaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"N\u00f8stdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmi","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette \u00d8degaard","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jpsychires.2026.03.014_bib1","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.3390\/life11121365","article-title":"Update on Statin treatment in patients with neuropsychiatric disorders","volume":"11","author":"Avan","year":"2021","journal-title":"Life"},{"issue":"1","key":"10.1016\/j.jpsychires.2026.03.014_bib2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13063-019-3822-5","article-title":"To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction\/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial","volume":"21","author":"Begemann","year":"2020","journal-title":"Trials"},{"issue":"7770","key":"10.1016\/j.jpsychires.2026.03.014_bib5","article-title":"Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial","volume":"341","author":"Chen","year":"2010","journal-title":"BMJ (Online)"},{"key":"10.1016\/j.jpsychires.2026.03.014_bib6","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1192\/bjp.146.5.464","article-title":"Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine\/placebo trial I. Course of illness, stability of diagnosis, and the role of a special maintenance clinic","volume":"146","author":"Curson","year":"1985","journal-title":"Br. J. Psychiatr. : J. Ment. Sci."},{"issue":"xxxx","key":"10.1016\/j.jpsychires.2026.03.014_bib7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.schres.2019.11.025","article-title":"Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia","volume":"225","author":"Emsley","year":"2020","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.jpsychires.2026.03.014_bib8","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S2215-0366(21)00078-X","article-title":"Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials","volume":"8","author":"H\u00f8jlund","year":"2021","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"10.1016\/j.jpsychires.2026.03.014_bib9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"9","key":"10.1016\/j.jpsychires.2026.03.014_bib10","doi-asserted-by":"crossref","first-page":"852","DOI":"10.2174\/1570159X17666190228113348","article-title":"Association between serum lipids and antipsychotic response in schizophrenia","volume":"17","author":"Kim","year":"2019","journal-title":"Curr. Neuropharmacol."},{"issue":"6","key":"10.1016\/j.jpsychires.2026.03.014_bib11","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/schbul\/sbv037","article-title":"Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method","volume":"41","author":"Leucht","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2026.03.014_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.695672","article-title":"Associations between relapses and psychosocial outcomes in patients with schizophrenia in real-world settings in the United States","volume":"12","author":"Lin","year":"2021","journal-title":"Front. Psychiatr."},{"issue":"15","key":"10.1016\/j.jpsychires.2026.03.014_bib13","doi-asserted-by":"crossref","first-page":"7078","DOI":"10.1017\/S0033291723000429","article-title":"Guided antipsychotic reduction to reach minimum effective dose (GARMED) in patients with remitted psychosis: a 2-year randomized controlled trial with a naturalistic cohort","volume":"53","author":"Liu","year":"2023","journal-title":"Psychol. Med."},{"issue":"4","key":"10.1016\/j.jpsychires.2026.03.014_bib14","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/s41380-019-0502-5","article-title":"The efficacy and heterogeneity of antipsychotic response in schizophrenia: a meta-analysis","volume":"26","author":"McCutcheon","year":"2019","journal-title":"Mol. Psychiatry 2019"},{"issue":"11","key":"10.1016\/j.jpsychires.2026.03.014_bib15","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S2215-0366(23)00258-4","article-title":"Antipsychotic dose reduction and discontinuation versus maintenance treatment in people with schizophrenia and other recurrent psychotic disorders in England (the RADAR trial): an open, parallel-group, randomised controlled trial","volume":"10","author":"Moncrieff","year":"2023","journal-title":"Lancet Psychiatry"},{"issue":"13","key":"10.1016\/j.jpsychires.2026.03.014_bib16","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1017\/S0033291724001910","article-title":"Deprescribing antipsychotics in patients with schizophrenia: findings from a specialized clinic","volume":"54","author":"N\u00f8stdal","year":"2024","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jpsychires.2026.03.014_bib17","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ps.20230641","article-title":"Motivations for and experiences with antipsychotic tapering among patients with schizophrenia seeking guided dose reduction","author":"N\u00f8stdal","year":"2024","journal-title":"Psychiatr. Serv."},{"issue":"1","key":"10.1016\/j.jpsychires.2026.03.014_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12888-020-02770-2","article-title":"\u201cit means so much for me to have a choice\u201d: a qualitative study providing first-person perspectives on medication-free treatment in mental health care","volume":"20","author":"Oedegaard","year":"2020","journal-title":"BMC Psychiatry"},{"issue":"4\u20135","key":"10.1016\/j.jpsychires.2026.03.014_bib19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1081\/DDC-54305","article-title":"Competitive displacement of clozapine from plasma proteins in normolipidemic and hyperlipidemic plasma samples: clinical implications","volume":"31","author":"Procyshyn","year":"2005","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jpsychires.2026.03.014_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2017.00741","article-title":"The complex relationship between antipsychotic-induced weight gain and therapeutic benefits: a systematic review and implications for treatment","volume":"11","author":"Raben","year":"2018","journal-title":"Front. Neurosci."},{"issue":"2","key":"10.1016\/j.jpsychires.2026.03.014_bib21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00004850-198904000-00001","article-title":"Guidelines for the dosage of neuroleptics. I: chlorpromazine equivalents of orally administered neuroleptics","volume":"4","author":"Rey","year":"1989","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.jpsychires.2026.03.014_bib22","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22r14490","article-title":"Comparative effects of 11 antipsychotics on weight gain and metabolic function in patients with acute schizophrenia: a dose-response meta-analysis","volume":"84","author":"Sab\u00e9","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.03.014_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115472","article-title":"Clinical improvement in schizophrenia during antipsychotic treatment in relation to changes in glucose parameters: a systematic review","volume":"328","author":"Smith","year":"2023","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.jpsychires.2026.03.014_bib24","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-016-1006-3","article-title":"Lipid profiles in schizophrenia associated with clinical traits: a five year follow-up study","volume":"16","author":"Solberg","year":"2016","journal-title":"BMC Psychiatry"},{"issue":"6","key":"10.1016\/j.jpsychires.2026.03.014_bib25","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/eip.12769","article-title":"Can antipsychotic dose reduction lead to better functional recovery in first-episode psychosis? A randomized controlled-trial of antipsychotic dose reduction. The reduce trial: study protocol","volume":"13","author":"Weller","year":"2019","journal-title":"Early Intervent. Psychiatry"},{"issue":"6","key":"10.1016\/j.jpsychires.2026.03.014_bib26","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s40263-020-00713-9","article-title":"Adherence to oral antipsychotics measured by electronic adherence monitoring in schizophrenia: a systematic review and meta-analysis","volume":"34","author":"Yaegashi","year":"2020","journal-title":"CNS Drugs"}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395626001639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395626001639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T05:42:24Z","timestamp":1779428544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395626001639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":24,"alternative-id":["S0022395626001639"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2026.03.014","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic parameters as a predictor of relapse in patients with schizophrenia undergoing tapering of antipsychotics","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2026.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}